Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and collaborations with external partners. While Anthropic avoids drug discovery to not compete with its pharma clients, it recently partnered with Novo Nordisk for joint drug discovery efforts. The move highlights the company's commitment to integrating AI with practical biological testing despite ongoing industry concerns about AI risks and calls for regulation.
Novo Nordisk, which recently partnered with Anthropic for drug discovery, trades at USD 43.29 on Pluang with a slight 1-day gain of 0.22%. The stock shows strong investor interest with 72% buy orders and a dividend yield of 4.16%. These figures are current as of Sep 19, 2026 06:21 WIB.
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
Novo Resources Corp. has released an updated corporate presentation outlining its strategic priorities, exploration results, and project advancements. The presentation highlights significant progress in Novo's gold exploration portfolio, including pr...
Novo Nordisk's Q3 results exceeded expectations, driven by a 53% increase in pill sales and strong net patient growth, dispelling fears of oral product cannibalization. The company is also reducing capital expenditures and expanding free cash flow, s...
